2020 Hyperalgesia Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Hyperalgesia pipeline report presents a comprehensive overview of the research and development of Hyperalgesia drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Three drugs in pre-clinical phase, one drug in Phase 1, and one drug in Phase 2
As of February 2020, the Hyperalgesia pipeline remains robust with 5 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Hyperalgesia treatment. Diverse types of targeted therapies are being explored through clinical trials including Cannabinoid receptor agonist; cyclooxygenase inhibitor; GPR4 antagonist; monoacylglycerol lipase (MGLL) inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Hyperalgesia drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Hyperalgesia pipeline drugs profiled in the report include- CR701, Drug for Hyperalgesia, ketoprofen, ABX-1431, GPR4 for Arthritis, Hyperalgesia and Oncology
As of February 2020, the Hyperalgesia pipeline remains robust with 5 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Hyperalgesia treatment. Diverse types of targeted therapies are being explored through clinical trials including Cannabinoid receptor agonist; cyclooxygenase inhibitor; GPR4 antagonist; monoacylglycerol lipase (MGLL) inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Hyperalgesia drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Hyperalgesia development
- Hyperalgesia pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Hyperalgesia pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Hyperalgesia pipeline candidates included
- Business overview and snapshot of all companies involved in Hyperalgesia pipeline are included
- Latest market and pipeline developments are provided in the report
Hyperalgesia pipeline drugs profiled in the report include- CR701, Drug for Hyperalgesia, ketoprofen, ABX-1431, GPR4 for Arthritis, Hyperalgesia and Oncology
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Hyperalgesia Condition
2.3 Hyperalgesia Pipeline Snapshot, 2020
2.4 Companies investing in Hyperalgesia pipeline therapeutics
2.5 Phase wise Hyperalgesia Pipeline Candidates
2.6 Most Researched Mechanism of Action of Hyperalgesia Pipeline Products
2.7 Route of Administration of Hyperalgesia Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Cara Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Charleston Laboratories Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Exodos Life Sciences Limited Partnership Overview, Contacts and ASD Pipeline Drugs
3.4 H. Lundbeck AS Overview, Contacts and ASD Pipeline Drugs
3.5 Novartis AG Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 CR701 Drug Details
4.1.1 CR701 Current Status
4.1.2 CR701 Drug Overview
4.1.3 CR701 Mechanism of Action
4.1.4 CR701 Licensing/Collaboration Companies
4.1.5 CR701 Clinical Trials
4.2 Drug for Hyperalgesia Drug Details
4.2.1 Drug for Hyperalgesia Current Status
4.2.2 Drug for Hyperalgesia Drug Overview
4.2.3 Drug for Hyperalgesia Mechanism of Action
4.2.4 Drug for Hyperalgesia Licensing/Collaboration Companies
4.2.5 Drug for Hyperalgesia Clinical Trials
4.3 ketoprofen Drug Details
4.3.1 ketoprofen Current Status
4.3.2 ketoprofen Drug Overview
4.3.3 ketoprofen Mechanism of Action
4.3.4 ketoprofen Licensing/Collaboration Companies
4.3.5 ketoprofen Clinical Trials
4.4 ABX-1431 Drug Details
4.4.1 ABX-1431 Current Status
4.4.2 ABX-1431 Drug Overview
4.4.3 ABX-1431 Mechanism of Action
4.4.4 ABX-1431 Licensing/Collaboration Companies
4.4.5 ABX-1431 Clinical Trials
4.5 GPR4 for Arthritis, Hyperalgesia and Oncology Drug Details
4.5.1 GPR4 for Arthritis, Hyperalgesia and Oncology Current Status
4.5.2 GPR4 for Arthritis, Hyperalgesia and Oncology Drug Overview
4.5.3 GPR4 for Arthritis, Hyperalgesia and Oncology Mechanism of Action
4.5.4 GPR4 for Arthritis, Hyperalgesia and Oncology Licensing/Collaboration Companies
4.5.5 GPR4 for Arthritis, Hyperalgesia and Oncology Clinical Trials
5. LATEST HYPERALGESIA PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Hyperalgesia Condition
2.3 Hyperalgesia Pipeline Snapshot, 2020
2.4 Companies investing in Hyperalgesia pipeline therapeutics
2.5 Phase wise Hyperalgesia Pipeline Candidates
2.6 Most Researched Mechanism of Action of Hyperalgesia Pipeline Products
2.7 Route of Administration of Hyperalgesia Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Cara Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Charleston Laboratories Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Exodos Life Sciences Limited Partnership Overview, Contacts and ASD Pipeline Drugs
3.4 H. Lundbeck AS Overview, Contacts and ASD Pipeline Drugs
3.5 Novartis AG Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 CR701 Drug Details
4.1.1 CR701 Current Status
4.1.2 CR701 Drug Overview
4.1.3 CR701 Mechanism of Action
4.1.4 CR701 Licensing/Collaboration Companies
4.1.5 CR701 Clinical Trials
4.2 Drug for Hyperalgesia Drug Details
4.2.1 Drug for Hyperalgesia Current Status
4.2.2 Drug for Hyperalgesia Drug Overview
4.2.3 Drug for Hyperalgesia Mechanism of Action
4.2.4 Drug for Hyperalgesia Licensing/Collaboration Companies
4.2.5 Drug for Hyperalgesia Clinical Trials
4.3 ketoprofen Drug Details
4.3.1 ketoprofen Current Status
4.3.2 ketoprofen Drug Overview
4.3.3 ketoprofen Mechanism of Action
4.3.4 ketoprofen Licensing/Collaboration Companies
4.3.5 ketoprofen Clinical Trials
4.4 ABX-1431 Drug Details
4.4.1 ABX-1431 Current Status
4.4.2 ABX-1431 Drug Overview
4.4.3 ABX-1431 Mechanism of Action
4.4.4 ABX-1431 Licensing/Collaboration Companies
4.4.5 ABX-1431 Clinical Trials
4.5 GPR4 for Arthritis, Hyperalgesia and Oncology Drug Details
4.5.1 GPR4 for Arthritis, Hyperalgesia and Oncology Current Status
4.5.2 GPR4 for Arthritis, Hyperalgesia and Oncology Drug Overview
4.5.3 GPR4 for Arthritis, Hyperalgesia and Oncology Mechanism of Action
4.5.4 GPR4 for Arthritis, Hyperalgesia and Oncology Licensing/Collaboration Companies
4.5.5 GPR4 for Arthritis, Hyperalgesia and Oncology Clinical Trials
5. LATEST HYPERALGESIA PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
